Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Class A Common Stock, $0.00001 par value per share
-
Shares outstanding
-
4,564,846
-
Total 13F shares
-
304,244,163
-
Share change
-
-1,095,976
-
Total reported value
-
$1,609,644,574
-
Put/Call ratio
-
96%
-
Price per share
-
$5.29
-
Number of holders
-
330
-
Value change
-
-$29,277,151
-
Number of buys
-
199
-
Number of sells
-
106
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) as of Q1 2025
As of 31 Mar 2025,
RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) was held by
330 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
304,244,163 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, BAILLIE GIFFORD & CO, BlackRock, Inc., SOFTBANK GROUP CORP., Kinnevik AB (publ), STATE STREET CORP, Mubadala Investment Co PJSC, Novo Holdings A/S, and MIC Capital Management UK LLP.
This page lists
332
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.